000781223 000__ 05657cam\a2200529Mi\4500
000781223 001__ 781223
000781223 005__ 20230306143225.0
000781223 006__ m\\\\\o\\d\\\\\\\\
000781223 007__ cr\nn\nnnunnun
000781223 008__ 161202s2017\\\\sz\a\\\\ob\\\\001\0\eng\d
000781223 019__ $$a964585818$$a964931388$$a974651424$$a981099330
000781223 020__ $$a9783319483603$$q(electronic book)
000781223 020__ $$a3319483609$$q(electronic book)
000781223 020__ $$z9783319483597
000781223 020__ $$z3319483595
000781223 0247_ $$a10.1007/978-3-319-48360-3$$2doi
000781223 035__ $$aSP(OCoLC)ocn966563464
000781223 035__ $$aSP(OCoLC)966563464$$z(OCoLC)964585818$$z(OCoLC)964931388$$z(OCoLC)974651424$$z(OCoLC)981099330
000781223 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dOCLCO$$dN$T$$dGW5XE$$dIDEBK$$dOCLCA$$dOCLCF$$dN$T$$dAZU$$dUAB$$dOCLCO$$dCOO$$dN$T$$dOCLCO$$dUPM$$dIOG$$dOCLCO$$dVT2
000781223 049__ $$aISEA
000781223 050_4 $$aRC270.3.T84$$bD35 2017eb
000781223 08204 $$a616.99/40756$$223
000781223 1001_ $$aDakubo, Gabriel D.,$$eauthor.
000781223 24510 $$aCancer Biomarkers in Body Fluids :$$bBiomarkers in Circulation /$$cGabriel D. Dakubo.
000781223 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2017]
000781223 300__ $$a1 online resource (xix, 519 pages) :$$billustrations.
000781223 336__ $$atext$$btxt$$2rdacontent
000781223 337__ $$acomputer$$2rdamedia
000781223 338__ $$aonline resource$$2rdacarrier
000781223 347__ $$atext file$$bPDF$$2rda
000781223 504__ $$aIncludes bibliographical references and index.
000781223 5050_ $$aPreface; Contents; About the Author; Chapter 1: Melanoma Biomarkers in Circulation; Key Topics; 1.1 Introduction; 1.2 Screening Recommendations for Melanoma; 1.3 Molecular Pathology of Melanoma; 1.3.1 BRAF Mutations in Melanoma; 1.3.2 RAS Mutations in Melanoma; 1.3.3 Alterations in Cell Cycle Control Genes in Melanoma; 1.3.4 TP53 Mutations in Melanoma; 1.3.5 KIT Mutations in Melanoma; 1.3.6 MITF Mutations in Melanoma; 1.3.7 PI3K Pathway Alterations in Melanoma; 1.3.8 Molecular Subtypes of Melanoma; 1.3.9 Molecular Progression Model of Melanoma; 1.4 Circulating Melanoma Biomarkers.
000781223 5058_ $$a1.4.1 Circulating Melanoma Cell-Free Nucleic Acid Biomarkers1.4.2 Circulating Melanoma Epigenetic Biomarkers; 1.4.3 Circulating Melanoma Genetic Biomarkers; 1.4.3.1 Mutations as Circulating Melanoma Biomarkers; 1.4.3.2 Circulating MSA as Melanoma Biomarkers; 1.4.4 Circulating Melanoma Coding RNA Biomarkers; 1.4.5 Circulating Melanoma Noncoding RNA Biomarkers; 1.4.6 Circulating Melanoma Protein Biomarkers; 1.4.6.1 Serum S100beta as Melanoma Biomarker; 1.4.6.2 Serum LDH as Melanoma Biomarker; 1.4.6.3 Serum MIA as Melanoma Biomarker; 1.4.6.4 Serum VEGF as Melanoma Biomarker.
000781223 5058_ $$a1.4.6.5 Serum Levodopa to l-Tyrosine Ratio as Melanoma Biomarker1.4.6.6 Serum Cysteinyldopa as Melanoma Biomarker; 1.4.6.7 Serum Autoantibodies as Melanoma Biomarkers; 1.4.6.8 Circulating Melanoma Proteomic Biomarkers; 1.4.7 Circulating Melanoma Cells; 1.4.7.1 Molecular Approaches to CMCs; 1.4.7.2 CMCs in Advanced Stage III and IV Melanoma; 1.4.7.3 CMCs in Uveal Melanoma; 1.4.8 Melanoma Extracellular Vesicles; 1.4.9 Summary; References; Chapter 2: Head and Neck Cancer Biomarkers in Circulation; Key Topics; 2.1 Introduction; 2.2 Screening Recommendations for HNC.
000781223 5058_ $$a2.3 The Need for Noninvasive Screening Tests for HNC2.4 Molecular Pathology of HNC; 2.4.1 Molecular Classification of HNC; 2.4.2 Molecular Pathology of HPV-Positive HNC; 2.4.3 Specific Genetic Alterations in HNC; 2.4.3.1 EGFR Alterations in HNC; 2.4.3.2 TGFbeta Pathway Alterations in HNC; 2.4.3.3 PI3K/AKT Pathway Alterations in HNC; 2.4.3.4 TP53 Alterations in HNC; 2.4.3.5 Cell Cycle Gene Alterations in HNC; 2.4.3.6 MET Alterations in HNC; 2.4.3.7 Telomere Alterations in HNC; 2.5 Circulating HNC Biomarkers; 2.5.1 Circulating Cell-Free Nucleic Acids as HNC Biomarkers.
000781223 5058_ $$a2.5.2 Circulating HNC Epigenetic Biomarkers2.5.3 Circulating HNC Noncoding RNA Biomarkers; 2.5.3.1 Oncomirs and Tumor Suppressormirs in HNC; 2.5.3.2 Circulating HNC miRNA Biomarkers; 2.5.4 Circulating HNC Serum Protein Biomarkers; 2.5.5 Circulating HNC Cells; 2.5.5.1 Methodologies for CHNCC Analysis; 2.5.5.2 CHNCCs as Staging Biomarkers; 2.5.5.3 CHNCCs as Prognostic Biomarkers; 2.5.5.4 CHNCCs as Predictive Biomarkers; 2.5.5.5 Induction of CHNCCs by Clinical Interventions; 2.5.6 Circulating HPV-Positive HNC Biomarkers; 2.5.7 HNC Extracellular Vesicles; 2.6 Nasopharyngeal Carcinoma.
000781223 506__ $$aAccess limited to authorized users.
000781223 520__ $$aThis book examines in depth the evidence, clinical applications and potential cancer signatures in the circulation and discusses alterations in circulating cell-free nucleic acids, and circulating tumor DNA, as well as the epigenome, genome, transcriptome (coding and noncoding), proteome (both traditional serum proteins and proteomic profiles) and metabolome. Further, it highlights the clinical applications of circulating tumor cells for each cancer type and addresses the emerging importance of extracellular vesicular contents, including miRNA, oncogenes and drug resistant factors. As such, it offers a valuable reference guide for cancer researchers, oncologists, clinicians, surgeons, medical students, oncology nurses, diagnostic laboratories, and the pharmaceutical industry.
000781223 588__ $$aDescription based on online resource; title from digital title page (viewed on December 19, 2016).
000781223 650_0 $$aCancer$$xMolecular diagnosis.
000781223 650_0 $$aCancer$$xGenetic aspects.
000781223 650_0 $$aBiochemical markers.
000781223 77608 $$iPrint version:$$z3319483595$$z9783319483597$$w(OCoLC)959033933
000781223 85280 $$bebk$$hSpringerLink
000781223 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-48360-3$$zOnline Access$$91397441.1
000781223 909CO $$ooai:library.usi.edu:781223$$pGLOBAL_SET
000781223 980__ $$aEBOOK
000781223 980__ $$aBIB
000781223 982__ $$aEbook
000781223 983__ $$aOnline
000781223 994__ $$a92$$bISE